A Study of AQUAVAN® Injection Versus Midazolam HCl for Sedation in Elderly Patients Undergoing Elective Colonoscopy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00209599|
Recruitment Status : Terminated
First Posted : September 21, 2005
Last Update Posted : November 7, 2008
|Condition or disease||Intervention/treatment||Phase|
|Colonoscopy Colon Polyps||Drug: fospropofol disodium||Phase 2|
This is a randomized, open-label study designed to assess the safety and efficacy of AQUAVAN ® Injection versus midazolam HCl following pretreatment with an analgesic, fentanyl citrate injection, in producing sedation in elderly patients undergoing colonoscopy.
Following completion of preprocedure sedation assessments, patients will be randomly assigned to 1 of the 2 i.v. treatment groups at a 4:1 (AQUAVAN®. Injection: midazolam HCl) allocation ratio. To ensure that a distribution of ages is obtained, enrollment will be stratified into 2 equal-size groups by age (>65 to <72 years of age and >72 years of age). Randomization will be stratified by site within each age group. All patients will receive fentanyl citrate injection as an analgesic pretreatment. Supplemental doses of fentanyl citrate injection may be administered if the patient reports pain or if inadequate analgesia is present as demonstrated by increased heart rate and/or blood pressure in the presence of adequate sedation.
At no time should fentanyl citrate injection be administered to increase sedation levels.
AQUAVAN®. Injection and midazolam HCl will be administered to induce a state of adequate sedation, defined as a Modified Observer's Assessment of Alertness/Sedation (OAA/S) score of 4 or less. Supplemental doses will be administered to increase depth or duration of sedation. Supplemental doses will not be administered if the Modified OAA/S score is 2 or less or if there is no purposeful response to stimulation. The depth of sedation will be measured by the Modified OAA/S scale, a validated measure. Patient and Investigator assessments will be used to confirm the depth of sedation provided met the goals of sedation, reduction of anxiety and reduced awareness.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase II, Randomized, Open-Label Study to Assess the Safety and Efficacy of AQUAVAN® Injection Versus Midazolam HCl for Sedation in Elderly Patients Undergoing Colonoscopy Procedures|
|Study Start Date :||February 2005|
|Actual Study Completion Date :||March 2005|
- The primary efficacy endpoint was Sedation Success defined as a patient having 3 consecutive Modified OAA/S scores ≤4 and completing the procedure without requiring alternative sedative medications and without requiring manual or mechanical ventilation.
- Measures of recovery and cognitive functions by the blinded evaluator
- Time to Fully Recovered from the end of the procedure
- Time to Fully Alert from the end of the procedure
- Change from baseline DSST score over time during the Recovery period
- Measures of sedation adequacy
- Modified OAA/S scores over time during the Dosing Initiation, Procedural, and Recovery periods
- Duration and percent of time when a patient's Modified OAA/S score is at each level between the first dose of study medication and Fully Alert, inclusive
- Duration of sedation
- Number of doses of study medication administered for the procedure
- Time to sedation
- Time that splenic flexure, hepatic flexure, and cecum are reached, and time to end of procedure
- Number of repositionings
- ·Number of procedure interruptions due to inadequate sedation
- Patient-reported outcome and Investigator's assessment
- Patient's rating of experience after Fully Recovered (including patient's level of sedation, memory recall, pain/discomfort, and willingness to be treated again);
- Patient's rating at 24-hour telephone survey (including time to normal food intake and time to resuming normal activities)
- Investigator's rating at the end of the procedure (including patient's level of sedation, pain/discomfort, anxiety, response to instructions, overall satisfaction with the study drug, and willingness to be use sedatives again)
- Blinded evaluator's rating after Fully Recovered
- Safety Variables
- The following were safety endpoints:
- Nature, frequency, severity, relationship to treatment, and outcome of all treatment emergent AEs (TEAEs)
- Airway management (manual repositioning, increased oxygen flow, verbal or tactile stimulation)
- Airway intervention (suction, manual ventilation, endotracheal intubation or other mechanical airway management)
- Sedation-related AEs (hypopnea, apnea, hypoxemia, bradycardia, hypotension,)
- Alternative sedation/hypnotic medications
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00209599
|Study Director:||James Jones, MD,PharmD||Eisai Inc.|